Review of 2022 ASCO-GU prostate cancer milestone studies

VernacularTitle:2022 ASCO-GU前列腺癌精粹解析
Author: Yao ZHU ¹ ; Sujun HAN
Author Information

1. 复旦大学附属肿瘤医院泌尿外科，上海　200032
Keywords: Prostatic neoplasms; Prostate cancer; Metastatic; New hormonal agent; Poly(ADP-ribose) polymerase inhibitor; Combination therapy
From: Chinese Journal of Urology 2022;43(4):253-256
CountryChina
Language:Chinese
Abstract: Prostate cancer is one of the most common malignancies in older men. Prostate cancer patients with distant metastasis often have a poor prognosis, and more than half of Chinese prostate cancer patients have developed distant metastasis at the time of initial diagnosis. In recent years, with the disclosure of the results of a number of global multi-center clinical trials, combination therapy and precision therapy have become two major themes in the treatment of metastatic prostate cancer (mPCa). The American Society of Clinical Oncology Genitourinary (ASCO-GU) Cancers Symposium is a grand meeting of the urologic oncology community. Several research advances reported at the meeting will help to update the treatment strategy of mPCa. This article interprets and comments on a number of milestone studies on mPCa treatment at the ASCO-GU 2022 annual meeting, with a view to providing help for the clinical treatment decisions of mPCa patients.